Tumor hyperthermia research progress and application prospect in tumoroids (Review)

Abstract

Tumor hyperthermia is the fifth tumor treatment method after surgery, chemotherapy, radiotherapy and biological therapy, and is also one of the important adjuvant treatment methods for tumors. Hyperthermia can not only directly eliminate tumor cells, but also stimulate the antitumor immune response of the body, and improve the sensitivity of tumor tissues to radiotherapy and chemotherapy. An organoid is a tissue-specific cell cluster formed by 3D culture of various types of cells derived from target organ stem cells, which can reproduce the functions of target organs in vivo . At present, the research models of hepatocellular carcinoma (HCC) in vitro are mainly 2D culture cell line models, and there is no clinical report on tumor hyperthermia using HCC tumoroids. It was hypothesized that this will be a promising research direction.

HPV status and immunohistochemical analysis of p16, p53 and PD‑L1 expression as prognostic biomarkers in patients with squamous cell anal cancer receiving definitive radiotherapy/chemoradiotherapy

“…In addition, mutational profiles that notably differ between HPV-positive and HPV-negative patients may be explored, as they could suggest multiple avenues for the investigation of targeted therapies in anal SCC ( 59 ). Also, hyperthermia could be considered as a potential means of increasing the sensitivity of cancer cells to therapeutic agents, inducing direct cytotoxicity, triggering anticancer immune responses and improving drug delivery, as supported by previous studies ( 60 , 61 ). Hypoxia-sensitizing methods may also be explored, particularly in radioresistant HPV-negative or p16-negative subgroups, as in the DAHANCA 5 trials ( 46 , 62 ).…”